Multiple Myeloma

Share

Program Content

Activities

  • Conference to Clinic Myeloma 2024
    CCO’s Conference to Clinic Highlights From ASH 2024 Annual Meeting: Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 17, 2025

    Expires: July 16, 2025

Activities

DREAMM 7 Belantamab Combo
DREAMM-7 Efficacy Update: Belantamab Mafodotin Plus Bortezomib, Dexamethasone vs Daratumumab Plus Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

Mezigdomide Plus Vd or Kd for RRMM
Mezigdomide Plus Vd or Kd in Relapsed/Refractory Multiple Myeloma: Updated Results From the CC-92480-MM-002 Phase I/II Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

Arlocabtagene Autoleucel
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-cell Therapy, in Heavily Pretreated Multiple Myeloma: Updated Phase I Study Results
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

IFM2017-03: Dara Len in Frail ND MM
IFM2017-03: Phase III Trial of Daratumumab Plus Lenalidomide Without Long-term Dexamethasone vs Lenalidomide and Dexamethasone in Frail Patients With Newly Diagnosed MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

MajesTEC 4
EMN30/MajesTEC-4: Safety Run-in Data From Phase III Trial of Teclistamab ± Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma After ASCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

AQUILA Daratumumab
AQUILA: Primary Results From the Phase III Trial of Daratumumab vs Active Monitoring for High-Risk Smoldering Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

Faculty

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation